Quoin Updates On Type C Meet With FDA For QRX003 In NS; On Track To Initiate Phase 3 Trial In 2026

Quoin Pharmaceuticals held a Type C meeting with the FDA regarding QRX003, its lead late-stage candidate for Netherton Syndrome, and issued a clinical and regulatory update. The article does not report an FDA approval or a definitive regulatory commitment or specific next steps. Absent concrete trial readouts or regulatory decisions, the update is informational and likely to have limited immediate market impact.

Analysis

Quoin Pharmaceuticals held a Type C meeting with the FDA regarding QRX003, its lead late-stage candidate for Netherton Syndrome, and issued a clinical and regulatory update. The article does not report an FDA approval or a definitive regulatory commitment or specific next steps. Absent concrete trial readouts or regulatory decisions, the update is informational and likely to have limited immediate market impact.